Episurf Medical receives reimbursement coverage for Episealer® Talus in Belgium
Episurf Medical (NASDAQ: EPIS B) today announces that reimbursement coverage has been established for the ankle technology, Episealer® Talus, in the Belgian market. The announcement follows a decision by the Insurance Committee of NIHDI (National Institute for Health and Disability Insurance), who has issued a positive decision for Episealer® Talus. The decision applies to both the private and the public markets in Belgium.
”We are continuing to make progress in all of our markets, and today’s announcement represents a critical step in our process of launching Episealer® Talus in the Belgian market”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on 22 February, 2022.
Tags: